Page last updated: 2024-11-02

4-phenylbutyric acid and Head and Neck Neoplasms

4-phenylbutyric acid has been researched along with Head and Neck Neoplasms in 1 studies

4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.

Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)

Research Excerpts

ExcerptRelevanceReference
"Cisplatin has been widely used to treat head and neck cancer."1.35Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. ( Burkitt, K; Ljungman, M, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Burkitt, K1
Ljungman, M1

Other Studies

1 other study available for 4-phenylbutyric acid and Head and Neck Neoplasms

ArticleYear
Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
    Molecular cancer, 2008, Mar-06, Volume: 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Fanconi Anemia Complementa

2008